Physician profile
Duc N Tran
NPI 1033204011
$16,589.12
in general payments reported to CMS, 2019-2025
28 companies · $2,370 in 2025
The $2,370 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,785 · 2020: $1,822 · 2021: $2,250 · 2022: $2,057 · 2023: $2,730 · 2024: $2,575 · 2025: $2,370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,634 · Education: $41.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,634.25 |
| Education | $41.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,962.25 | 2019-2025 | Vemlidy |
| Amgen INC. | $2,925.36 | 2019-2025 | Repatha, Evenity, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,485.49 | 2019-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $1,439.14 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,422.03 | 2019-2025 | Taltz, Jardiance, Emgality |
| Janssen Pharmaceuticals, INC | $1,282.86 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $695.88 | 2019-2024 | Shingrix, Arexvy, Bexsero |
| Novartis Pharmaceuticals Corporation | $599.23 | 2019-2025 | |
| Novo Nordisk INC | $589.31 | 2020-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $482.26 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amarin Pharma, INC. | $413.37 | 2019-2022 | |
| Pfizer INC. | $412.54 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $369.16 | 2024-2025 | Gemtesa |
| Abbvie INC. | $338.12 | 2019-2025 | Ubrelvy |
| Phathom Pharmaceuticals, INC. | $270.02 | 2024-2025 | Voquezna |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $226.34 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $136.90 | 2024-2025 | Zenpep |
| Leo Pharma INC. | $135.62 | 2023 | Adbry |
| Genzyme Corporation | $125.67 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.31 | 2021-2024 | Trulance, Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $36.50 | 2021-2025 | |
| Sanofi Pasteur INC. | $26.90 | 2025 | |
| Allergan, INC. | $22.61 | 2020 | |
| Radius Health, INC. | $20.77 | 2022 | |
| Exact Sciences Corporation | $19.11 | 2025 | Cologuard Collection Kit |
| Genentech USA, INC. | $17.88 | 2020 | |
| Arbor Pharmaceuticals, INC. | $17.84 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $15.65 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duc Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.